VFDB - anti-virulence compound N-(2-{(2Z)-2-[1-(1,3-benzodioxol-5-ylmethyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene]hydrazinyl}-2-oxoethyl)pyridine-3-carboxamide

Acinetobacter

Aeromonas

Anaplasma

Bacillus

Bartonella

Bordetella

Brucella

Burkholderia

Campylobacter

Chlamydia

Clostridium

Corynebacterium

Coxiella

Enterococcus

Escherichia

Francisella

Haemophilus

Helicobacter

Klebsiella

Legionella

Listeria

Mycobacterium

Mycoplasma

Neisseria

Pseudomonas

Rickettsia

Salmonella

Shigella

Staphylococcus

Streptococcus

Vibrio

Yersinia

N-(2-{(2Z)-2-[1-(1,3-benzodioxol-5-ylmethyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene]hydrazinyl}-2-oxoethyl)pyridine-3-carboxamide

Drug details:
Molecular formula: C₂₄H₁₉N₅O₅

Standard name: N-[2-[[1-(1,3-benzodioxol-5-ylmethyl)-2-hydroxyindol-3-yl]diazenyl]-2-oxoethyl]pyridine-3-carboxamide

Classification: Amino acids, peptides, and analogues; Carboxylic acids and derivatives; Organic acids and derivatives; Organic compounds;

Curated SMILES: O=C(CNC(=O)C1=CC=CN=C1)N/N=C1\C(=O)N(CC2=CC3=C(C=C2)OCO3)C2=C1C=CC=C2

Chemical structure:

Evidence for compound's anti-virulence activity:

Acinetobacter
Related VFcategory: Regulation
Target: OmpR
Drug effect: Inhibits OmpR DNA binding to block downstream virulence pathways.
Max phase: Preclinical (in vivo)
Publication:
Trebosc V, et al., 2022. Targeting virulence regulation to disarm Acinetobacter baumannii pathogenesis. Virulence 13(1):1868-1883.


	Back to Top

2004-2025 NIPB, CAMS&PUMC